Median Technologies at the 50th I-ELCAP Conference on Lung Cancer Screening

Median Technologies, in collaboration with its US subsidiary eyonis Inc., is preparing to present its eyonis® LCS solution at the 50th I-ELCAP conference. This international event, taking place from October 22 to 24, 2026 in New York, focuses on lung cancer screening and brings together global experts in the field.

The French company highlights the advancements of its artificial intelligence technology, which is FDA-approved and CE-marked. Primarily targeting the American and European markets, the eyonis® LCS solution aims to facilitate early and consistent large-scale detection of lung cancers.

Two key presentations will highlight advancements in predicting malignancy in pulmonary nodules and the integration of foundational models into nodule detection and diagnosis. Median is reinforcing its leadership position in supporting the development of low-dose CT screening while addressing healthcare system challenges. The I-ELCAP conference is therefore a strategic showcase for Median, contributing to strengthening its commitment to innovation and international collaboration.